Hamburg Warns Some Of Congress’ ‘Cures’ May Be ‘Dangerous’
This article was originally published in The Gray Sheet
Executive Summary
Outgoing FDA Commissioner also cautions against unfunded mandates in Energy & Commerce’s biomedical reform proposal.
You may also be interested in...
Hamburg: Neither U.S. Nor EU Device Regulation Has It Completely Right
During her final public appearance at the National Press Club, outgoing FDA Commissioner Margaret Hamburg defended her tenure and said she was leaving a stronger FDA than the one she inherited. Asked about the agency's device regulatory process, she said she didn't know if FDA or Europe had struck the right balance but said more work needs to be done.
Breakthrough Device Route, Registries On Wish List At Senate Hearing
Industry stakeholders listed their priorities to improve the medical regulatory process and research during a second hearing at the Senate Health, Education, Labor and Pensions Committee which is working on its own version of the House's 21st Century Cures bill.
AdvaMed Innovation Agenda Aligns With Capitol Hill Objectives
A review of the medical device trade group's “Innovation Agenda” for the coming year and the recent 21st Century Cures proposal in Congress suggests a supportive environment for the association's priorities.